Article | June 22, 2021

Considerations For Early Stage Gene Therapy Start-Ups: From Clinical Development To Manufacturing To Commercialization

Source: Precision ADVANCE
Gene Therapy

In 2020, nearly $20 billion of funding poured into the advanced therapy sector, reflecting the enthusiasm of researchers and investors in the transformative potential of these novel treatments.

Recently, Precision ADVANCE hosted Considerations for Early Stage Gene Therapy Start-ups: From Clinical Development to Manufacturing to Commercialization, an expert panel discussion moderated by Anshul Mangal, President of Project Farma and Precision ADVANCE. Precision ADVANCE is a collection of interconnected services and complementary teams uniquely focused on the complexities of gene therapies and the resources needed to bring these advanced therapeutics successfully to market.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene